Page 10 - Quick Inventory News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the New England Journal of Medicine yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder . The study was designed and conducted by a research … C...

Scientific American Psilocybin Therapy May Work as Well as Common Antidepressant For the first time, a randomized controlled trial shows the psychedelic offers potent, if short-term, relief in comparison with an SSRI Print Psilocybin, the active ingredient in “magic mushrooms,” may provide relief from depression symptoms that is equivalent to, or better than, an SSRI antidepressant. Credit: Getty Images Advertisement The first randomized controlled trial to compare the illicit psychedelic psilocybin with a conventional selective serotonin reuptake inhibitor (SSRI) antidepressant found tha...

email article Psilocybin -- "magic mushrooms" -- failed to improve symptoms of depression over a selective serotonin reuptake inhibitor (SSRI) in a 59-patient phase II trial, though the study's leaders are not ready to give up on the hallucinogen. At 6 weeks, psilocybin did not have a significantly greater effect on symptoms of moderate-to-severe major depressive disorder compared with the SSRI escitalopram (Lexapro), as measured by mean change from baseline on the 16-item Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR-16) score, with a between-group difference ...

Mount Sinai Researchers from the Icahn School of Medicine at Mount Sinai have identified a drug that works against depression by a completely different mechanism than existing treatments. Their study showed that ezogabine (also known as retigabine), a drug that opens KCNQ2/3 type of potassium channels in the brain, is associated with significant improvements in depressive symptoms and anhedonia in patients with depression. Anhedonia is the reduced ability to experience pleasure or lack of reactivity to pleasurable stimuli; it is a core symptom of depression and associated with worse outcomes,...

Landmark heart study reveals new insights about risk factors for depression Recently published UT Southwestern research reveals new insights about risk factors for depression based on data from a landmark longitudinal study focused on heart disease. One study, published in the Journal of Clinical Psychiatry, shows a link between an inflammatory molecule in the blood and a person's likelihood of depressive symptoms. The other study, in the journal Maturitas, indicates which symptoms of menopause are most predictive of depression. Both studies are based on data from the Dallas Heart Study (DH...